Rachel Eren
Profile
Rachel Eren is the founder of Pink Biopharma Ltd.
She worked as the Chief Executive Officer at Xl Therapeutics Ltd.
and as the Vice President-Research at Intellect Neurosciences, Inc. from 2006 to 2010.
She also worked as the Vice President-Clinical Development at Andromeda Biotech Ltd.
Dr. Eren holds a graduate and doctorate degree from the Weizmann Institute of Science.
Former positions of Rachel Eren
| Companies | Position | End |
|---|---|---|
Pink Biopharma Ltd.
 Pink Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Pink Biopharma Ltd. engages in the development of novel immune checkpoint inhibitor against a protein expressed on cancer tissue, which acts as an inhibitory ligand for natural killer cells. The company was founded by Rachel Eren, Yael Yoffe-Mizrahi, and Angel Porgador and is headquartered in Tel Aviv, Israel. | Chief Executive Officer | - |
Andromeda Biotech Ltd.
 Andromeda Biotech Ltd. Pharmaceuticals: MajorHealth Technology Andromeda Biotech Ltd. develops treatment for autoimmune diabetes. The company was founded in 2007 and is headquartered in Rehovot, Israel. | Chief Tech/Sci/R&D Officer | - |
Xl Therapeutics Ltd.
 Xl Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Xl Therapeutics Ltd. operates as biopharmaceutical company. It aims to develop small molecule compounds to treat patients suffering from Wiskott-Aldrich syndrome and X-linked thrombocytopenia, rare primary human immunodeficiencies that are caused by the absence and suboptimal function of the WAS protein. The company was founded in May 2016 and is headquartered in Ness Ziona, Israel. | Chief Executive Officer | - |
| INTELLECT NEUROSCIENCES, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Rachel Eren
| Weizmann Institute of Science | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 4 |
|---|---|
Intellect Neurosciences, Inc.
 Intellect Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Intellect Neurosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of disease-modifying therapeutic agents. It specializes in treatment and prevention of neurodegenerative conditions, collectively known as proteinopathies, which include alzheimer's, parkinson's and huntington disease. The company was founded by Daniel G. Chain on April 25, 2005 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
Andromeda Biotech Ltd.
Andromeda Biotech Ltd. Pharmaceuticals: MajorHealth Technology Andromeda Biotech Ltd. develops treatment for autoimmune diabetes. The company was founded in 2007 and is headquartered in Rehovot, Israel. | Health Technology |
Xl Therapeutics Ltd.
Xl Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Xl Therapeutics Ltd. operates as biopharmaceutical company. It aims to develop small molecule compounds to treat patients suffering from Wiskott-Aldrich syndrome and X-linked thrombocytopenia, rare primary human immunodeficiencies that are caused by the absence and suboptimal function of the WAS protein. The company was founded in May 2016 and is headquartered in Ness Ziona, Israel. | Health Technology |
Pink Biopharma Ltd.
Pink Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Pink Biopharma Ltd. engages in the development of novel immune checkpoint inhibitor against a protein expressed on cancer tissue, which acts as an inhibitory ligand for natural killer cells. The company was founded by Rachel Eren, Yael Yoffe-Mizrahi, and Angel Porgador and is headquartered in Tel Aviv, Israel. | Health Technology |
- Stock Market
- Insiders
- Rachel Eren
